Binds Cancer Cell Or Component Or Product Thereof (e.g., Cell-surface Antigen, Etc.) Patents (Class 530/388.8)
-
Patent number: 8591889Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: GrantFiled: April 1, 2009Date of Patent: November 26, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Patent number: 8586716Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: GrantFiled: August 3, 2007Date of Patent: November 19, 2013Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Jeff Hsu, Linda Masat, Judy Abraham, Masahisa Handa, Siew Schleyer
-
Patent number: 8569459Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.Type: GrantFiled: May 23, 2012Date of Patent: October 29, 2013Assignee: Medimmune, LLCInventors: David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
-
Patent number: 8563692Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).Type: GrantFiled: January 5, 2011Date of Patent: October 22, 2013Assignee: The Regents of the University of CaliforniaInventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
-
Patent number: 8551480Abstract: The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.Type: GrantFiled: August 30, 2010Date of Patent: October 8, 2013Assignees: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 8551490Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.Type: GrantFiled: July 18, 2011Date of Patent: October 8, 2013Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8546546Abstract: An antibody that binds to Mucin17 (Muc17) is disclosed. The antibody of the present invention preferably binds to the peptide of SEQ ID NO:3 and does not bind to the peptide of SEQ ID NO:4 or the peptide of SEQ ID NO:5. Also disclosed are an anti-cancer agent, preferably an anti-cancer agent for pancreatic cancer, which comprises the antibody of the present invention, as well as a method of diagnosing cancer using the antibody of the present invention, preferably the antibody of the present invention that does not bind to the secreted-form of Muc17.Type: GrantFiled: July 3, 2008Date of Patent: October 1, 2013Assignee: Forerunner Pharma Research Co., Ltd.Inventor: Kiyotaka Nakano
-
Patent number: 8536118Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.Type: GrantFiled: September 29, 2009Date of Patent: September 17, 2013Assignee: Genentech, Inc.Inventors: Monica Kong-Beltran, Dineli M. Wickramasinghe
-
Publication number: 20130236470Abstract: Provided is a novel therapeutic agent specific for a malignant tumor expressing MHC class II. The present invention provides an antibody recognizing a protein constituting MHC class II expressed on a malignant tumor, the antibody comprising at least one selected from heavy chain CDR1 (amino acid sequence represented by positions 49 to 54 of SEQ ID NO: 54), heavy chain CDR2 (amino acid sequence represented by positions 69 to 84 of SEQ ID NO: 54), heavy chain CDR3 (amino acid sequence represented by positions 117 to 128 of SEQ ID NO: 54), light chain CDR1 (amino acid sequence represented by positions 46 to 55 of SEQ ID NO: 56), light chain CDR2 (amino acid sequence represented by positions 71 to 77 of SEQ ID NO: 56), and light chain CDR3 (amino acid sequence represented by positions 100 to 108 of SEQ ID NO: 56).Type: ApplicationFiled: October 4, 2011Publication date: September 12, 2013Applicants: JUNTENDO EDUCATINAL FOUNDATION, RIKENInventors: Shuji Matsuoka, Yasuyuki Ishii
-
Patent number: 8529902Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 17, 2003Date of Patent: September 10, 2013Assignee: Genmab A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Patent number: 8529891Abstract: The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells.Type: GrantFiled: November 22, 2010Date of Patent: September 10, 2013Assignee: Trustees of Tufts CollegeInventors: Daniel G Jay, Brenda K Eustace, Takashi Sakurai
-
Patent number: 8524868Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: November 9, 2009Date of Patent: September 3, 2013Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Patent number: 8524672Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: August 19, 2011Date of Patent: September 3, 2013Assignee: Biogen Idec MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson
-
Patent number: 8524867Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.Type: GrantFiled: August 14, 2007Date of Patent: September 3, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
-
Patent number: 8524233Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: September 4, 2008Date of Patent: September 3, 2013Assignee: Biocon Limited & Centro de Immunologia MolecularInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 8518403Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: GrantFiled: July 15, 2005Date of Patent: August 27, 2013Assignee: Amgen Research (Munich) GmbHInventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Raum
-
Patent number: 8513028Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.Type: GrantFiled: May 8, 2007Date of Patent: August 20, 2013Assignee: Creagene Inc.Inventors: Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
-
Patent number: 8512702Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: December 14, 2011Date of Patent: August 20, 2013Assignee: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Patent number: 8497355Abstract: A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.Type: GrantFiled: September 26, 2008Date of Patent: July 30, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Taichi Kuramochi, Hirotake Shiraiwa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Takahiro Ishiguro
-
Patent number: 8491906Abstract: The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other preferred embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.Type: GrantFiled: March 11, 2003Date of Patent: July 23, 2013Assignees: Philogen S.p.A., Bayer Schering Pharma AGInventors: Laura Borsi, Barbara Carnemolla, Enrica Balza, Patrizia Castellani, Luciano Zardi, Matthias Friebe, Christoph-Stephan Hilger
-
Patent number: 8486657Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.Type: GrantFiled: March 22, 2010Date of Patent: July 16, 2013Inventors: Xiaohong Cai, Thomas Cai
-
Patent number: 8486394Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.Type: GrantFiled: November 8, 2011Date of Patent: July 16, 2013Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 8481038Abstract: The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.Type: GrantFiled: November 14, 2011Date of Patent: July 9, 2013Assignee: Five Prime Therapeutics, Inc.Inventor: Harold Keer
-
Patent number: 8476410Abstract: Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed.Type: GrantFiled: October 15, 2009Date of Patent: July 2, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Xinhui Wang, Soldano Ferrone
-
Patent number: 8470330Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.Type: GrantFiled: July 28, 2010Date of Patent: June 25, 2013Assignees: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Patent number: 8465741Abstract: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.Type: GrantFiled: September 14, 2007Date of Patent: June 18, 2013Assignee: MMRGlobal, Inc.Inventors: Gerhard Frey, Bruce E. Kimmel, Abraham Anderson
-
Patent number: 8461304Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: June 9, 2010Date of Patent: June 11, 2013Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Patent number: 8461310Abstract: A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin ?v?3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin ?v?1-dependent cell adhesion, and so on.Type: GrantFiled: February 12, 2009Date of Patent: June 11, 2013Assignees: Gene Techno Science Co., Ltd., National University Corporation Hokkaido UniversityInventors: Toshimitsu Uede, Yutaka Matsui
-
Patent number: 8461308Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.Type: GrantFiled: October 13, 2010Date of Patent: June 11, 2013Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
-
Patent number: 8449885Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.Type: GrantFiled: June 17, 2010Date of Patent: May 28, 2013Assignee: Genentech, Inc.Inventors: Yu-Ju G. Meng, Kyu H. Hong, Johnny Gutierrez
-
Patent number: 8444972Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.Type: GrantFiled: August 5, 2010Date of Patent: May 21, 2013Assignee: University of MassachusettsInventors: Kenneth L. Rock, Dancella Fernandes
-
Patent number: 8445211Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.Type: GrantFiled: July 10, 2008Date of Patent: May 21, 2013Assignees: bioMerieux, Centre National de la Recherche Scientifique, Institut CurieInventors: Monique Arpin, Nicole Battail-Poirot, Corinne Beaulieu, Jean-Philippe Charrier, Genevieve Choquet-Kastylevsky
-
Patent number: 8425876Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.Type: GrantFiled: February 9, 2010Date of Patent: April 23, 2013Assignee: The Brigham and Women's Hospital, Inc.Inventors: Markus H. Frank, Mohamed H. Sayegh
-
Patent number: 8414896Abstract: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.Type: GrantFiled: November 12, 2010Date of Patent: April 9, 2013Assignee: Symphogen A/SInventors: Mikkel Wandahl Pedersen, Lucilla Steinaa, Allan Jensen, Klaus Koefoed, Per-Johan Meijer, Robert Carlsson, Charles Pyke, Lars Sogaard Nielsen
-
Patent number: 8399202Abstract: Novel immuno-interactive fragments of the ?C portion of a mammalian inhibin ? subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the ?C portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.Type: GrantFiled: March 30, 2009Date of Patent: March 19, 2013Assignee: Prince Henry's Institute of Medical ResearchInventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
-
Patent number: 8399207Abstract: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.Type: GrantFiled: January 3, 2011Date of Patent: March 19, 2013Assignee: Maine Medical CenterInventors: Lucy Liaw, Ah-Kau Ng
-
Patent number: 8394931Abstract: This invention concerns a panel of monoclonal antibodies against the High Mobility Group A 1 protein (HMGA1) and a process for preparing them, as well as the use of said antibodies for the quantitative determination of HMGA1 in biological fluids or in protein Iy sates deriving from lymphocyte cells. This invention also concerns a diagnostic kit for assessing risk factors related to the expression of the HMGA1 proteins.Type: GrantFiled: April 29, 2009Date of Patent: March 12, 2013Assignee: Areta International S.R.L.Inventors: Alfredo Fusco, Antonio Orlandi, Maria Luisa Nolli
-
Patent number: 8394924Abstract: The present invention features engineered proteins that include a first polypeptide that specifically binds a first target (e.g., a cellular target, such as a cell-surface antigen) and a second polypeptide that selectively binds an activating FcR.Type: GrantFiled: October 23, 2009Date of Patent: March 12, 2013Assignee: Massachusetts Institute of TechnologyInventors: K. Dane Wittrup, Shanshan Wu Howland
-
Patent number: 8394767Abstract: The present invention is directed to methods of treating cancer and preventing cancer metastasis in a subject by administering a modulator of CGRP receptor signaling. The present invention is further directed to methods of identifying novel compounds that inhibit CGRP receptor signaling, and reagents and animal models useful for the same.Type: GrantFiled: January 10, 2011Date of Patent: March 12, 2013Assignee: University of RochesterInventors: Ian M. Dickerson, Edward B. Brown
-
Patent number: 8394376Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: GrantFiled: December 7, 2010Date of Patent: March 12, 2013Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Patent number: 8389227Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: June 5, 2009Date of Patent: March 5, 2013Assignees: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recera I Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres
-
Patent number: 8388973Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: December 30, 2010Date of Patent: March 5, 2013Assignee: Genentech, Inc.Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
-
Patent number: 8383117Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: GrantFiled: June 10, 2005Date of Patent: February 26, 2013Assignee: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Georges Bosc, Francina C. Chahal
-
Patent number: 8383123Abstract: Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided.Type: GrantFiled: January 20, 2012Date of Patent: February 26, 2013Assignee: Genentech, Inc.Inventors: Daniel K. Kirchhofer, Rajesh Vij
-
Patent number: 8377435Abstract: Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell. A preferred polyvalent agent is an IgM, and enhanced cell wounding and killing can be provided by the addition of a crosslinking agent. At sublethal concentrations in vivo, the cell wounding antibodies permeabilize cells and dramatically enhance response to chemotherapeutic agents, even in patients refractory to the chemotherapeutic agents.Type: GrantFiled: November 4, 2005Date of Patent: February 19, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Neelima M. Bhat, Marcia M. Bieber, Nelson N. H. Teng, Martin E. Sanders
-
Publication number: 20130039974Abstract: The present invention is directed to antibodies binding to the MUC1 cytoplasmic domain and methods of using such antibodies to treat, diagnose, detect and monitor cancers that express the MUC1 antigen.Type: ApplicationFiled: August 10, 2012Publication date: February 14, 2013Inventors: Donald W. Kufe, Surender Kharbanda
-
Patent number: 8367353Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: GrantFiled: March 6, 2009Date of Patent: February 5, 2013Assignee: Roche MTM Laboratories AGInventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20130022614Abstract: The present invention provides monoclonal IgE antibodies comprising Fc epsilon (?) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).Type: ApplicationFiled: February 14, 2012Publication date: January 24, 2013Inventors: MANUEL L. PENICHET, BIRGIT C. SCHULTES, CHRISTOPHER F. NICODEMUS, TRACY R. DANIELS, GUSTAVO HELGUERA, JOSE A. RODRIGUEZ
-
Patent number: 8349585Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: GrantFiled: April 14, 2011Date of Patent: January 8, 2013Assignee: Alper Biotech, LLCInventor: Özge Alper
-
Patent number: 8350011Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: August 2, 2007Date of Patent: January 8, 2013Assignee: MedImmune LimitedInventors: Susan Ann Cartlidge, Jianying Dong, Mark Hickinson, Ian Foltz, Jaspal Singh Kang